Tirzepatide approved for weight loss treatment by regulator The Medicines and Healthcare products Regulatory Agency has said tirzepatide will be available to patients with obesity, or who are overweight, with weight-related health problems.…
Community pharmacies to supply free COVID-19 tests to at-risk groups Eligible patients will be able to collect lateral flow device test kits from community pharmacies that have signed up to provide the service.…
NICE recommends drug treatment for long-term insomnia Daridorexant has been recommended as a second-line treatment for long-term insomnia by the National Institute for Health and Care Excellence.…
NICE guidance ‘addresses the high unmet need’ for treatment of acute migraine The National Institute for Health and Care Excellence has recommended rimegepant for acute migraine — the first available oral treatment for the condition.…
NICE recommends tirzepatide for type 2 diabetes in final draft guidance Following additional analyses and modelling of clinical and cost effectiveness, the National Institute for Health and Care Excellence has recommended tirzepatide for type 2 diabetes mellitus.…
‘Limited’ supply of weight loss drug semaglutide launched in UK Manufacturer Novo Nordisk said it will monitor demand and work with regulators to ensure Wegovy is accessible to eligible patients.…
NHS weight-loss drugs could be prescribed via apps, says NICE draft guidance Some of the apps that could be made available include the ability to prescribe weight-loss management medication to eligible patients.…
Tirzepatide not recommended for treating type 2 diabetes, says NICE draft guidance Experts say the news is "disheartening" given the current shortages of GLP-1 receptor agonists.…
NICE recommends new chronic heart failure treatment following discussions with manufacturer Data suggest that up to 150,000 people in England would be eligible for treatment with dapagliflozin.…
Medicated wafer to be approved for the treatment of frequent migraines on the NHS Rimegepant will be available on the NHS for patients who have tried at least 3 other preventative therapies, and have at least 4 and fewer than 15 migraine attacks per month.…
